Anhui Huaheng Biotechnology Stock Debt To Equity

688639 Stock   29.49  1.44  4.66%   
Anhui Huaheng Biotechnology fundamentals help investors to digest information that contributes to Anhui Huaheng's financial success or failures. It also enables traders to predict the movement of Anhui Stock. The fundamental analysis module provides a way to measure Anhui Huaheng's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anhui Huaheng stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Anhui Huaheng Biotechnology Company Debt To Equity Analysis

Anhui Huaheng's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

Anhui Total Stockholder Equity

Total Stockholder Equity

1.18 Billion

At present, Anhui Huaheng's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.
According to the company disclosure, Anhui Huaheng Biotechnology has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The debt to equity for all China stocks is 100.0% higher than that of the company.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Anhui Fundamentals

About Anhui Huaheng Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Anhui Huaheng Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anhui Huaheng using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anhui Huaheng Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Anhui Stock

Anhui Huaheng financial ratios help investors to determine whether Anhui Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Anhui with respect to the benefits of owning Anhui Huaheng security.